“Today, patients want to get diagnosis and treatment faster with fewer visits to the doctor’s office. They want speedier and more comprehensive delivery of clinical services, be it laboratory tests, imaging, or other procedures. Core laboratories have something unique and irreplaceable. Core laboratories will continue to anchor lab testing services in the communities they serve. What
Tag: near-patient testing
“Today, patients want to get diagnosis and treatment faster with fewer visits to the doctor’s office. They want speedier and more comprehensive delivery of clinical services, be it laboratory tests, imaging, or other procedures.”
—Ralph Taylor, President, Sysmex America, Inc.
CEO Summary: To bring testing closer to patients, clinical laboratories will need to offer sophisticated point-of-care systems
CEO SUMMARY: Market clearance of the first-ever CLIA waived analyzer for complete blood count and three-part differential tests could cut time-to-answer from days to mere minutes for one of the top 20 tests by volume performed at core laboratories. Developer Sysmex America, Inc., foresees its analyzer as a complement to central labs. Basic diagnostics would
CEO SUMMARY: Despite the burdens of CLIA certification and reduced reimbursement for lab tests, many medical practice experts are advising doctors to expand in-office testing. However, diagnostic technologies for near-patient testing are still not robust enough to support this trend. Early attempts to expand testing in physicians’ office laboratories show the technology is still not
CEO SUMMARY: It’s a story that will soon become a national headline. Even as laboratories struggle to find enough med techs to fill open positions, hospitals are facing an even bigger problem in getting enough nurses to keep units staffed and open. Recruiting nurses overseas is one solution—but will the American lab industry try the
THERE’S PLENTY OF HOOROAR AND EXCITEMENT about skyrocketing stock prices for several public lab and pathology companies in 2000! But this crusty old curmudgeon has been around the investment industry too long to accept Wall Street’s new-found enthusiasm for clinical laboratories as definitive proof of the lab industry’s financial turnaround.
For example, it’s exciting to see the
CEO SUMMARY: Qualigen, Inc. gained FDA approval to sell its FastPack™ System for PSA testing in the United States. Qualigen is one more example of a technology company that expects to shift diagnostic testing out of core laboratories and closer to the patient. Initially Qualigen will sell this system to urologists, where it believes the
CEO SUMMARY: Pick your trend: declining reimbursement, consolidation, clinical integration, downsizing, and capitated reimbursement. These trends all continued to shape the way laboratories organized to provide services. But 1997’s wildcard was the federal government. Between investigations and new regulations, laboratories were hit hard.
FOR THE clinical laboratory industry, 1997’s biggest surprise was both unexpected and unpleasant:
CEO SUMMARY: Look for the Quest-Sonora joint venture to be followed by others in coming months. Competition and marketplace realities are forcing the three national laboratories to respond with groundbreaking strategies. Hospital laboratory partners in these deals can reap significant benefits with savvy negotiations.
SHARED EQUITY VENTURES between hospitals and commercial laboratories are tough to make
The story in your February 17 issue about laboratory automation as viewed by an industrial engineer was fascinating. He did a great job of helping me understand how to look at clinical laboratory automation. However, you say nothing about the centralized/decentralized issue. Isn’t automation predicated on the concept of a centralized laboratory with a